Needham analyst Joseph Stringer reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of $32.00. The company’s shares opened today at $28.04.
Stringer covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Cidara Therapeutics, and Moderna. According to TipRanks, Stringer has an average return of 9.7% and a 48.56% success rate on recommended stocks.
Currently, the analyst consensus on Vir Biotechnology is a Moderate Buy with an average price target of $58.33.
See the top stocks recommended by analysts >>
VIR market cap is currently $3.88B and has a P/E ratio of 3.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
Read More on VIR:
- Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
- Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
- Vir Biotechnology achieves target enrollment for Phase 2 PENINSULA trial